IGF2R and neoplasm: Our previous work demonstrated the preferential tumor localization of the radiolabeled monoclonal antibodies (mAbs) to human IGF2R (mAb MEM-238) and to human and murine IGF2R (mAb 2G11) in OS xenografts and patients derived xenografts (PDX) in mice in comparison with the control mAbs.